Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia

Inclusion Criteria: * History of type 1 diabetes between 2 and 30 years * Receiving daily insulin injections or insulin pump therapy for at least 2 years * If patient is taking Lantus, Levemir or equivalent once-daily in the evening as basal insulin, must be willing to transition to once-daily in the morning at least 48 hours prior to 1st dosing, and to follow this dosing regimen for the entire duration of the study * Body mass index (BMI) greater than or equal to 20.00 and below or equal to 33.00 kg/m2 * Female patients must not be pregnant, and must be using effective contraception. * Light-, non- or ex-smokers. A light smoker is defined as someone smoking 10 cigarettes or less per day for at least 3 months before day 1 of this study. An ex smoker is defined as someone who completely stopped smoking for at least 6 months before day 1 of this study Exclusion Criteria: * History of an episode of severe hypoglycemia (as defined by an episode that required third party assistance for treatment) in the previous 6 months before day 1 of this study * Score ≥4 on the Clarke Hypoglycemia Awareness survey at screening * Presence or history of pheochromocytoma (i.e. adrenal gland tumor) * Presence or history of significant upper respiratory or allergic (i.e., seasonal rhinitis) disease * Presence of clinically significant findings on nasal examination and bilateral anterior rhinoscopy * Known presence of hereditary problems of galactose and /or lactose intolerance * History of significant hypersensitivity to glucagon or any related products as well as severe hypersensitivity reactions (like angioedema) to any drugs